Inmagene Biopharmaceuticals Completes Merger With Ikena Oncology [UPDATED]
July 25, 2025
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
Redacted RnD Announces Acquisition of Maserati Formula E Team
February 19, 2025
Cooley advised Redacted RnD, a company founded by Brooklyn Earick with a focus on technology, sports, and media and entertainment, on its acquisition of the Maserati Formula E team.
Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology
December 23, 2024
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
Cooley Advises on Candid Therapeutics’ $370 Million Capital Raise, Three-Way Merger
September 9, 2024
Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.